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Intra-tumour heterogeneity is an important diagnostic, therapeutic and prognostic challenge. 
Its extent and mechanism in brain tumours is incompletely understood[1]. We describe a 
malignant tumour with unique pathological and genetic features. Most notably the tumour 
contained mutations in the SMARCB1 gene (typically associated with Atypical 
Teratoid/Rhabdoid Tumours[2]), the H3F3A gene (typically associated with high grade glioma 
in children[3]) and the BRAF gene. Furthermore, there was marked heterogeneity in mutation 
load between different parts of the tumour. This heterogeneity has implications both for the 
evolution of the tumour and for its diagnosis.  
A previously healthy 14-year-old girl presented with acute onset of headache, vomiting, 
blurred vision, olfactory and gustatory hallucinations, and flashes of past experience. MRI 
scan of the brain showed a localized heterogeneous haemorrhagic lesion in the left mesial 
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temporal region (Figure 1). She underwent subtotal tumour resection and was then treated 
with cranio-spinal irradiation. However, residual tumour persisted through treatment and she 
had cytological evidence of CSF dissemination. She died three months after presentation.  
The tumour (Figure 2) was of high cellularity and consisted of large cells with eosinophilic 
cytoplasm and large vesicular nuclei. Some cells had prominent nucleoli. There were frequent 
mitotic figures and apoptotic bodies, and moderate to severe nuclear pleomorphism. Some 
areas resembled a glioblastoma by virtue of areas of pseudo-palisading necrosis. There was 
no microvascular proliferation, no Rosenthal fibres, and no eosinophilic granular bodies. In 
some areas, there was a myxoid stroma, vascular reaction and tumour reticulin deposition. 
Immunostaining was positive for vimentin and showed patchy reactivity for desmin, EMA, 
synaptophysin, CD34, but was negative for SMA, neurofilament and cytokeratin. There were 
a few foci of GFAP-positive tumour cells throughout the tumour but most tumour cells were 
negative. The Ki67 labelling index was very high. There was a mixture of parts of the tumour 
where many of the tumour cells retained INI-1 immunoreactivity (‘region 1’) and other parts of 
the tumour where most of the tumour cells showed loss of INI1 immunoreactivity (‘region 2’).  
Genetic heterogeneity was demonstrated by sequencing of the coding regions of SMARCB1 
gene, exon 15 of the BRAF gene and exon 1 of the HIST1H3B and H3F3A genes from the 2 
regions of the tumour.  SMARCB1 gene copy number was demonstrated using MLPA. 
A 2bp duplication was detected in exon 5 of the SMARCB1 gene, leading to a frameshift 
mutation c.560_561dupCC (Figure 3). This results in a predicted truncated protein 
p.Ile189Profs*21. We examined the mutation in two regions of the tumour; one of which 
showed residual INI1 staining with only focal loss (‘region 1’) and in one of which most cells 
were negative for INI-1 (‘region 2’). The mutation was detected reproducibly at high levels in 
region 2 but only at low levels in region 1. MLPA using SMARCB1 Kit P258 (MRC Holland, 
Amsterdam, the Netherlands) demonstrated loss of heterozygosity (LOH) for the entire 
SMARCB1 gene and several additional genes within the 22q11 region only in region 1 but not 
region 2. However, it should be noted that the limit of detection with MLPA is high which may 
have masked the extent of LOH in these heterogeneous samples. 
A c.1799T>A mutation was detected in exon 15 of the BRAF gene in both areas, resulting in 
the amino acid change p.Val600Glu. The mutation load in region 1 was greater than that 
observed in region 2 (Figure 3). 
Histones 3.1 (HIST1H3B) and 3.3 (H3F3A) were analysed by Sanger sequencing.  The region 
encompassing codons Lys28 and Gly35, commonly mutated in paediatric high-grade gliomas, 
was assessed using the current Reference Sequences, NP_003528.1 (HIST1H3B) and 
NP_002098.1(H3F3A).  Historically these codons have often been referred to as Lys27 and 
Gly34 in the literature.  A c.83A>T missense mutation was detected in the H3F3A gene in 
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region 1 resulting in the protein change p.Lys28Met (Figure 3).  This mutation was not 
detected in region 2 allowing for the limit of detection of Sanger sequencing of approximately 
20%.  Region 1 showed the presence of two variants in the HIST1H3B gene, c.174G>A and 
c.267G>A. These variants are predicted to result in synonymous polymorphisms; 
p.(Ser58Ser) and p.(Ala89Ala) respectively. These two variants were not detected in the DNA 
extracted from region 2. The p.Ala89Ala variant has been reported in a small number of 
healthy individuals in the dbSNP database, rs139461801 (NCBI). The other variant, 
p.Ser58Ser has not been reported in any of the on-line databases. The presence of this 
polymorphism in region 1 but not region 2 may either represent LOH in region 2 or somatic 
variants in region 1.  
We have described an unusual malignant brain tumour with areas that had histopathological 
features consistent with both glioblastoma and AT/RT. This morphological variability was 
reflected in striking genetic heterogeneity (summarised in Table 1). Uniquely, this tumour has 
a combination of mutations in SMARCB1, H3F3A and BRAF. We detected the SMARCB1 
mutation at the highest levels in the parts of the tumour that showed histological features of 
an ATRT (i.e. INI1 loss by immunohistochemistry). In contrast, we only found mutations in the 
H3F3A gene in the parts that showed retained INI1 staining. The V600E BRAF mutation was 
present in both regions examined but was present at a higher level in the INI1-retained 
region. The mutation in SMARCB1 is novel and is predicted to generate a truncated protein.  
To the best of our knowledge this pattern of morphology with matched genetic heterogeneity 
has not been previously described. It raises a number of diagnostic possibilities. The first is 
that this is a rhabdoid glioblastoma (R-GBM). R-GBM is a rare subtype of GBM, which may 
be morphologically indistinguishable from AT/RT. INI-1 staining is usually retained, but can be 
focal, or the level of expression can be low in the rhabdoid cells[4] but mutations in the 
SMARCB1 gene have not been seen [5].  
The second possibility is that this is an example of an ATRT arising from a pre-existing 
tumour. The development of ATRT-like tumours has been rarely described in the context of 
other, often low grade, tumours[6-8].  
Finally, our findings suggest the alternative explanation that the two components of this 
tumour have evolved out of a single precursor lesion, which lacked mutations in SMARCB1 or 
H3F3A but may have had a mutation in BRAF. Out of that precursor lesion, one component 
developed a mutation in SMARCB1 and one component developed a mutation in H3F3A. 
This heterogeneity has important implications for the mechanism of tumour evolution. In 
addition, it has implications for diagnosis, as sequencing of single regions may not identify the 
spectrum of mutations in the tumour. 
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Figure Legends 
Figure 1 Coronal FLAIR (left hand panel) and post-contrast coronal T1-weighted images (right 
hand panel) showing a well-defined, heterogeneous mass centred in the left mesial temporal 
region with some internal haemorrhage and rim and basal nodular enhancement. 
Figure 2 Histological images of the tumour including areas resembling a high-grade 
astrocytoma (Region 1) with pseudo-palisading necrosis (A) with retained INI-1 staining (C) 
and areas containing rhabdoid cells (B) with loss of INI-1 staining (D) (Region 2). A few small 
collections of tumour cells in both regions express GFAP but most tumour cells were negative 
(E-Region 1, F-Region 2). Scale bars: 50 µm. 
Figure 3 Sequencing of SMARCB1 (A), BRAF (B) and H3F3A (C). The top panels show 
region 1, the middle panels region 2 and the lower panel show a wild type control. A 
SMARCB1 mutation is present in region 2 and at low levels in region 1. The BRAF mutation is 
present in both samples but is at a higher level in region 1. The H3F3A mutation is present 
only in region 1. The arrows show the site of the mutations. 
Table 1: A summary of the main genetic findings in the two regions of the tumour. 
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 Region 1 Region 2 
INI1 
immunohistochemistry Mostly retained Mostly lost 
SMARCB1 insertion Present at very low levels Present at high levels 
SMARCB1 LOH Present Absent 
V600E BRAF mutation Present Present (at lower levels than region 1) 
H3F3A mutation Present Absent 
HIST1H3B 
polymorphisms Present Absent 
 
 



